350 related articles for article (PubMed ID: 26782663)
21. Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy.
Chalmer TA; Kalincik T; Laursen B; Sorensen PS; Magyari M;
J Neurol; 2019 Feb; 266(2):306-315. PubMed ID: 30515628
[TBL] [Abstract][Full Text] [Related]
22. Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity.
Spelman T; Horakova D; Ozakbas S; Alroughani R; Onofrj M; Kalincik T; Prat A; Terzi M; Grammond P; Patti F; Csepany T; Boz C; Lechner-Scott J; Granella F; Grand'Maison F; van der Walt A; Zhu C; Butzkueven H;
Mult Scler Relat Disord; 2023 Feb; 70():104477. PubMed ID: 36746088
[TBL] [Abstract][Full Text] [Related]
23. Characteristics influencing therapy switch behavior after suboptimal response to first-line treatment in patients with multiple sclerosis.
Teter B; Agashivala N; Kavak K; Chouhfeh L; Hashmonay R; Weinstock-Guttman B
Mult Scler; 2014 Jun; 20(7):830-6. PubMed ID: 24277325
[TBL] [Abstract][Full Text] [Related]
24. Use of glatiramer acetate between 2010-2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients.
Zecca C; Disanto G; Sacco R; Riccitelli GC; Gobbi C
BMC Neurol; 2019 Jul; 19(1):159. PubMed ID: 31299922
[TBL] [Abstract][Full Text] [Related]
25. Disability progression
von Wyl V; Benkert P; Moser A; Lorscheider J; Décard B; Hänni P; Lienert C; Kuhle J; Derfuss T; Kappos L; Yaldizli Ö
Mult Scler; 2021 Mar; 27(3):439-448. PubMed ID: 32463336
[TBL] [Abstract][Full Text] [Related]
26. Cognitive dysfunction in patients with multiple sclerosis treated with first-line disease-modifying therapy: a multi-center, controlled study using the BICAMS battery.
Cinar BP; Kösehasanoğulları G; Yigit P; Ozakbas S
Neurol Sci; 2017 Feb; 38(2):337-342. PubMed ID: 27885448
[TBL] [Abstract][Full Text] [Related]
27. Effect of lateral therapy switches to oral moderate-efficacy drugs in multiple sclerosis: a nationwide cohort study.
Buron MD; Kalincik T; Sellebjerg F; Sørensen PS; Magyari M
J Neurol Neurosurg Psychiatry; 2021 May; 92(5):556-562. PubMed ID: 33436501
[TBL] [Abstract][Full Text] [Related]
28. Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register.
Paolicelli D; Lucisano G; Manni A; Avolio C; Bonavita S; Brescia Morra V; Capobianco M; Cocco E; Conte A; De Luca G; De Robertis F; Gasperini C; Gatto M; Gazzola P; Lus G; Iaffaldano A; Iaffaldano P; Maimone D; Mallucci G; Maniscalco GT; Marfia GA; Patti F; Pesci I; Pozzilli C; Rovaris M; Salemi G; Salvetti M; Spitaleri D; Totaro R; Zaffaroni M; Comi G; Amato MP; Trojano M;
J Neurol; 2019 Dec; 266(12):3098-3107. PubMed ID: 31535270
[TBL] [Abstract][Full Text] [Related]
29. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.
Meca-Lallana JE; de Mingo-Casado P; Amorin-Díaz M; Martínez-Navarro ML; Barreiro AF
Clin Ther; 2010 Jun; 32(6):1061-6. PubMed ID: 20637960
[TBL] [Abstract][Full Text] [Related]
30. Effect of combined IFNbeta-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis.
Dhib-Jalbut S; Chen M; Henschel K; Ford D; Costello K; Panitch H
Mult Scler; 2002 Dec; 8(6):485-91. PubMed ID: 12474988
[TBL] [Abstract][Full Text] [Related]
31. Comparative efficacy of switching to natalizumab in active multiple sclerosis.
Spelman T; Kalincik T; Zhang A; Pellegrini F; Wiendl H; Kappos L; Tsvetkova L; Belachew S; Hyde R; Verheul F; Grand-Maison F; Izquierdo G; Grammond P; Duquette P; Lugaresi A; Lechner-Scott J; Oreja-Guevara C; Hupperts R; Petersen T; Barnett M; Trojano M; Butzkueven H
Ann Clin Transl Neurol; 2015 Apr; 2(4):373-87. PubMed ID: 25909083
[TBL] [Abstract][Full Text] [Related]
32. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis.
Prosperini L; Giannì C; Leonardi L; De Giglio L; Borriello G; Galgani S; Pozzilli C; Gasperini C
Mult Scler; 2012 Jan; 18(1):64-71. PubMed ID: 21828195
[TBL] [Abstract][Full Text] [Related]
33. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.
Vermersch P; Czlonkowska A; Grimaldi LM; Confavreux C; Comi G; Kappos L; Olsson TP; Benamor M; Bauer D; Truffinet P; Church M; Miller AE; Wolinsky JS; Freedman MS; O'Connor P;
Mult Scler; 2014 May; 20(6):705-16. PubMed ID: 24126064
[TBL] [Abstract][Full Text] [Related]
34. Treatment withdrawal in relapsing-remitting multiple sclerosis: a retrospective cohort study.
Lus G; Signoriello E; Maniscalco GT; Bonavita S; Signoriello S; Gallo C
Eur J Neurol; 2016 Mar; 23(3):489-93. PubMed ID: 26212486
[TBL] [Abstract][Full Text] [Related]
35. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis.
Chiao E; Meyer K
Curr Med Res Opin; 2009 Jun; 25(6):1445-54. PubMed ID: 19422279
[TBL] [Abstract][Full Text] [Related]
36. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
Devonshire V; Havrdova E; Radue EW; O'Connor P; Zhang-Auberson L; Agoropoulou C; Häring DA; Francis G; Kappos L;
Lancet Neurol; 2012 May; 11(5):420-8. PubMed ID: 22494956
[TBL] [Abstract][Full Text] [Related]
37. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Cohen JA; Barkhof F; Comi G; Hartung HP; Khatri BO; Montalban X; Pelletier J; Capra R; Gallo P; Izquierdo G; Tiel-Wilck K; de Vera A; Jin J; Stites T; Wu S; Aradhye S; Kappos L;
N Engl J Med; 2010 Feb; 362(5):402-15. PubMed ID: 20089954
[TBL] [Abstract][Full Text] [Related]
38. Glatiramer acetate is a treatment option in neutralising antibodies to interferon-beta-positive patients.
Capobianco M; Rizzo A; Malucchi S; Sperli F; Di Sapio A; Oggero A; Zaffaroni M; Ghezzi A; Bertolotto A
Neurol Sci; 2008 Sep; 29 Suppl 2():S227-9. PubMed ID: 18690500
[TBL] [Abstract][Full Text] [Related]
39. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
Fox RJ; Miller DH; Phillips JT; Hutchinson M; Havrdova E; Kita M; Yang M; Raghupathi K; Novas M; Sweetser MT; Viglietta V; Dawson KT;
N Engl J Med; 2012 Sep; 367(12):1087-97. PubMed ID: 22992072
[TBL] [Abstract][Full Text] [Related]
40. Prediction of relapse activity when switching to cladribine for multiple sclerosis.
Zhong M; van der Walt A; Monif M; Hodgkinson S; Eichau S; Kalincik T; Lechner-Scott J; Buzzard K; Skibina O; Van Pesch V; Butler E; Prevost J; Girard M; Oh J; Butzkueven H; Jokubaitis V
Mult Scler; 2023 Jan; 29(1):119-129. PubMed ID: 35894247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
